Cognition in schizophrenia: From basic science to clinical treatment

Psychopharmacology

Volumn 169, Issue 3-4, 2003, Pages 213-214

  Harvey, Philip D ^a   Geyer, Mark A ^b   Robbins, Trevor W ^c   Krystal, John H ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UK   (United Kingdom)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; COGNITION; COGNITIVE DEFECT; EDITORIAL; FUNCTIONAL DISEASE; HUMAN; MEMORY DISORDER; MENTAL HEALTH; NEUROBIOLOGY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOPHYSIOLOGY; SCHIZOPHRENIA;

ANIMALS; BIOMEDICAL RESEARCH; COGNITION; HUMANS; SCHIZOPHRENIA; SCIENCE;

EID: 0141993559     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1581-0     Document Type: Editorial

References (4)

1. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330
2. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff?" Schizophr Bull 26:119-136
3. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080-1086
4. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299:350-351